|
Gordeeva O.O., Bokova S.E.
Adherence to adjuvant hormonal therapy for luminal HER2-negative breast cancer: results of a patient survey
|
№6 / 2024
|
|
Gordeeva O.O.
Assessing the risk of recurrence of luminal HER2-negative breast cancer and the possibility of intensifying adjuvant hormonal therapy to reduce the risk of progression
|
№6 / 2024
|
|
V.F. Semiglazov, P.V. Krivorotko, N.B. Bekkeldieva, A.V. Komyakhov, A.S. Emelyanov, A.O. Gorina
The role of cyclin-dependent kinase inhibitors in adjuvant therapy of breast cancer
|
№14 / 2023
|
|
V.F. Semiglazov, P.V. Krivorotko, N.B. Bekkeldieva, A.O. Gorina, A.V. Komyakhov, R.M. Paltuev, T.T. Tabagua, S.S. Ereshenko
Trastuzumab deruxtecan in the treatment of breast cancer
|
№11 / 2023
|
|
G.A. Dashyan, E.S. Dzhelialov, V.V. Konstantinova, Yu.A. Gronskaya, A.D. Murskikh, R.M. Akhmedov, A.E. Tyusenko, A.A. Olchonova, Z.V. Dyakonenko, O.A. Sereda, A.M. Belousov
Primary resistance to anti-HER2 therapy: mechanisms of development and ways to overcome
|
№11 / 2023
|
|
R.V. Orlova, M.I. Gluzman, A.A. Vakhitova
Possibilities of overcoming hormone resistance in patients with metastatic HR+ HER2- breast cancer using the drug alpelisib in various subgroups in real clinical practice
|
№11 / 2023
|
|
I.S. Gulian, E.P. Bystritskaya, N.Yu. Otstavnykh, E.V. Khudchenko, E.V. Eliseeva, V.I. Apanasevich, M.P. Isaeva
GSTT1 and GSTM1 deletion polymorphism as a predictor of response to hormonal therapy for breast cancer
|
№11 / 2023
|
|
G.A. Dashyan, V.V. Konstantinova, E.S. Dzhelialov, R.M. Akhmedov, Yu.V. Semiletova, A.S. Zhurov, A.E. Tyusenko, A.A. Olchonova, I.A. Pavlikova, A.M. Belousov
Delay of initiation of adjuvant chemotherapy in patients with early breast cancer: causes and consequences
|
№11 / 2023
|
|
Sh.G. Khakimova, A.D. Zikiryakhodzhaev, A.D. Kaprin, G.G. Khakimova, I.M. Onofriychuk, E.A. Rasskazova, A.S. Sukhotko, M.Yu. Vlasova, A.R. Bosieva, V.K. Tokaev
Reconstructive plastic surgery of the breast using autogenous tissue. Historical aspects
|
№11 / 2023
|
|
R.S. Pesotsky, V.F. Semiglazov, P.V. Krivorotko, T.T. Tabagua, K.Yu. Zernov, A.S. Emelyanov, S.S. Ereshchenko, N. Amirov, V.V. Mortada, D.G. Ulrikh, V.E. Levchenko, K.Yu. Rychagov, K.Yu. Zirov, V.N. Evseev
Analysis of the effectiveness of various neoadjuvant chemotherapy regimens in patients with T1-3N1-3M0 I–IIIC stage locally advanced breast cancer
|
№6-7 / 2023
|
|
R.S. Pesotsky, V.F. Semiglazov, P.V. Krivorotko, T.T. Tabagua, K.Yu. Zernov, A.S. Emelyanov, T.Yu. Semiglazova, N. Amirov, V.V. Mortada, D.G. Ulrikh, V.E. Levchenko, K.Yu. Rychagov, K.Yu. Zirov, V.N. Evseev
Evaluation of long-term results of treatment of patients with residual tumors (including those with minimal forms of ypT1abN0), with pathomorphological complete response (pCR) after neoadjuvant systemic therapy, with primary minimal breast cancer (pT1abN0M0)
|
№6-7 / 2023
|
|
E.O. Golubenko, M.I. Savelyeva, Zh.A. Sozaeva, I.V. Poddubnaya, V.V. Korennaya
Clinical significance of genetic polymorphism of tamoxifen metabolic enzymes and transporters in breast cancer: results of a population-based cohort study
|
№11-12 / 2022
|
Русский
